Shionogi Builds Women's Health And Sexual Health Portfolio With QuatRx Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Shionogi Pharma will pay $25 million upfront and up to $100 million in milestone payments for selective estrogen receptor modulator ospemifene, which it expects to file in the second half for the treatment of postmenopausal vulvovaginal atrophy.